Firm to Research Cannabis Treatments Under NIH Deal

A pharmaceutical company has inked a licensing agreement with the National Institutes of Health (NIH) to develop, test and possibly sell cannabis-based drugs for use in treating head trauma.

Under the agreement, KannaLife Sciences will research CBD and other cannabis-derived treatments for chronic traumatic encephalopathy (CTE), a degenerative brain condition most common among athletes who played contact sports.

The disease has received widespread press in recent years in relation to the long-term health of retired professional football players.

NIH has not publicly commented on the arrangement.

KannaLife – based in New York – won approval from the NIH several years ago to conduct research on potential treatments for ailments tied to liver issues.

Daily News | Ancillary Marijuana Companies | Briefs | Legal & Regulatory News for Marijuana Businesses | National Medical Cannabis Business & Marijuana Legal News

 2 Comments

  1. Doc August 5, 2014
  2. CannaBiDial.com August 8, 2014

Leave a Reply

Your email address will not be published. Required fields are marked *

Please note: Comments are moderated by our editors who do their best to approve comments ASAP. As Marijuana Business Daily is focused on business, we approve comments that are specifically relevant to industry professionals. General opinions and questions about cannabis may not be posted.